If fatty liver disease represents a primary treatment target alongside weight loss, Mazdutide offers well-documented efficacy
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
Professional medical evaluation may be appropriate when: Facial hollowing or volume loss is the primary concern Skin laxity is significant There is persistent redness, itching, pain, or a new rash Hair shedding becomes pronounced or continues for several months Dryness is severe despite a simplified routine A changing lesion or pigmented spot requires evaluation The individual is considering injectable or energy-based procedures Consumers should not stop, reduce, or change a prescribed GLP-1 medication because of cosmetic concerns without speaking with the healthcare professional managing their treatment
They target different receptors and were designed to be complementary which is exactly why cagrilintide is studied in combination with an incretin (semaglutide) rather than against one
Studies have also demonstrated changes in other inflammatory markers, including fibrinogen, plasminogen activator inhibitor-1 (PAI-1), and various adhesion molecules involved in vascular inflammation
Cardiovascular and Renal Benefits Beyond glycemic control, GLP-1 receptor agonists have demonstrated significant cardiovascular and renal benefits
